MindWalk (NASDAQ:HYFT) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of MindWalk (NASDAQ:HYFT) from a strong sell rating to a hold rating in a report released on Monday,Zacks reports.

A number of other research firms have also recently commented on HYFT. HC Wainwright reaffirmed a “buy” rating on shares of MindWalk in a research report on Monday, July 20th. Wall Street Zen raised shares of MindWalk from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $5.00.

MindWalk Price Performance

HYFT stock opened at $1.48 on Monday. MindWalk has a 52-week low of $0.99 and a 52-week high of $2.99. The company has a quick ratio of 1.75, a current ratio of 1.84 and a debt-to-equity ratio of 0.43. The stock has a market cap of $69.13 million, a price-to-earnings ratio of -5.69 and a beta of 0.82. The business has a fifty day moving average of $1.36 and a two-hundred day moving average of $1.37.

MindWalk (NASDAQ:HYFT) last announced its quarterly earnings results on Monday, September 14th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.04). The business had revenue of $2.73 million during the quarter, compared to analyst estimates of $3.25 million. MindWalk had a negative net margin of 105.11% and a negative return on equity of 133.26%. As a group, research analysts anticipate that MindWalk will post -0.21 earnings per share for the current year.

Hedge Funds Weigh In On MindWalk

A hedge fund recently bought a new stake in MindWalk stock. GSA Capital Partners LLP purchased a new position in shares of MindWalk Holdings Corp. (NASDAQ:HYFT) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 34,525 shares of the company’s stock, valued at approximately $55,000. GSA Capital Partners LLP owned 0.07% of MindWalk at the end of the most recent reporting period. 6.70% of the stock is owned by institutional investors and hedge funds.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.